Trials / Completed
CompletedNCT01102114
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
A Second Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,000 (actual)
- Sponsor
- Nabi Biopharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NicVAX Vaccine | NicVAX vaccine given 6 times over 6 months |
| BIOLOGICAL | Placebo Vaccine | Placebo vaccine given 6 times over 6 months |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2010-04-12
- Last updated
- 2012-05-09
Locations
25 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01102114. Inclusion in this directory is not an endorsement.